SHAREHOLDER NEWSLETTER December 2024 A MESSAGE FROM THE BCAL LEADERSHIP TEAM Jayne Shaw, Executive Chair; John Hurrell, Non-Executive Director; and Shane Ryan, CEO Dear Shareholders, As the holiday season draws near, we are filled with pride and gratitude as we reflect on an extraordinary year for BCAL — a year that has brought us closer than ever to revolutionising women’s health. Together, we are transforming 14 years of dedicated research into real-world impact, a milestone worth celebrating. Our purpose at BCAL has always been clear: to improve the lives of women through innovative, patient-centric healthcare solutions. This year, that purpose has been brought into sharp focus as we've navigated the complexities of clinical development and regulatory approvals, culminating in the upcoming soft launch of our BREASTEST® in Q1CY2025. We are on the verge of something remarkable, and we cannot wait for what lies ahead for our company in 2025. Our momentum is a testament to the collective efforts of our team, partners, and shareholders. To our advocacy partners, So Brave and the Sydney Breast Cancer Foundation, thank you for your unwavering support. To the doctors and women who participated in our clinical studies, your contributions have been invaluable. To you, our shareholders, we extend our deepest gratitude. And to the BCAL team and Board, your dedication and guidance are the driving force behind this success. As we close this transformative year, we want to wish you and your families a joyful and restful holiday season. May it be filled with warmth, happiness, and the excitement of new possibilities. Thank you for being part of the BCAL family — we look forward to sharing more milestones with you in 2025. Warmest holiday wishes, Shane Ryan, CEO, and Jayne Shaw, Executive Chair on behalf of the BCAL Diagnostics Leadership Team A Summary of 2024 This has been a big year for BCAL Diagnostics, our biggest one yet! We've made incredible progress – both commercially and clinically – laying the groundwork for the highly anticipated launch of BREASTEST® in Q1CY2025. Here's a look back at the key milestones that have defined our journey in 2024: New additions to our management team and board brought sharper focus on our commercialization journey: Shane Ryan transitioned from COO to become the new CEO, with Dr John Hurrell moving from CEO to board member and consultant. David Darling also joined the board, both David and John have extensive experience supporting companies in similar stages to ours. Raised over $10 million dollars: we were ecstatic to see the support of new and existing shareholders to our oversubscribed capital raise in June. The funds we raised have helped us support our product development and expansion to the US. Accelerated our clinical collaborations across NSW and Victoria: we’ve extended our clinician network within the two states, with the goal of laying the foundation for the seamless roll out of our technology. Scientific progress: we’ve made significant progress of BREASTEST® and it is almost ready to take to market. US Operations: In September, we began our US operations by acquiring a lab, building a team and bringing clinical sites on board to collect local samples for our US study. First commercial partnership signed: we have entered into a partnership with Sydney Breast Clinic to be the first site to offer our BREASTEST® adjunct to mammogram. NATA Accreditation: After months of meticulous and lots of hard work from the entire team, we have received NATA accreditation for our North Ryde lab, a fantastic milestone towards commercialisation. In the last two months… NATA Accreditation BCAL received NATA accreditation on 12 December 2024, a formal acknowledgement of the quality and reliability of our lab, ensuring that it meets the highest accuracy standards. Awarded for the laboratory’s quality systems, the accreditation instils confidence in healthcare providers and patients, guaranteeing that our test delivers reliable results. Soft Launch of BREASTEST® at Sydney Breast Clinic The Sydney Breast Clinic will be the first location to offer our BREASTEST® alongside their mammograms. This partnership brings us closer to making accessible, accurate screening a reality. The Sydney Breast Clinic is one of Australia's foremost multi-disciplinary breast screening clinics, and their experienced team will work closely with us to ensure seamless integration of the test into their service offerings, providing doctors and patients with additional information for breast health management. Full announcement here Events ASX Small and Mid-Cap Conference Sydney, 25 September 2024 BCAL had the opportunity to present at the ASX Small and Mid-Cap Conference. With 355 attendees both online and in person, the presentation primarily attracted new and intermediate investors eager to learn more about BCAL's business vision, strategy, and progress. The event provided a valuable platform for BCAL to share its achievements and future goals with a broader investor audience. You can watch Jayne’s presentation in the link below: North Ryde Laboratory Visit In celebration of Breast Cancer Awareness Month, BCAL on 15 October welcomed shareholders to our facility in North Ryde for a panel discussion about advancements in diagnostics and how BCAL can contribute to the early detection of breast cancer. Shane Ryan, CEO of BCAL, and Jayne Shaw, Executive Chair welcomed our esteemed guests to the facility and presented the company’s latest developments. Around 30 guests attended the event and got an inside look into our state-of-the-art laboratory. The presentation was followed by a tour of the facility, showcasing and explaining the equipment our team will use to process our tests in house. Sydney Breast Cancer Foundation Ladies Lunch On 25 October, the Sydney Breast Cancer Foundation hosted its sold-out 20th annual Ladies Lunch, bringing together a community united by the shared experience of breast cancer. BCAL Diagnostics proudly supported this highly anticipated event, with its leadership team in attendance, celebrating two decades of this meaningful gathering. BCAL’s Executive Chair spoke to an audience for more than 1.200 women about our work to bring BREASTEST® to market, as well as sharing her personal and professional experience supporting patients with breast cancer. IN THE NEWS Jayne Shaw’s post-event interview (ASX Small and Mid-cap Conference) Proactive Investors BCAL's blood-test cancer breakthrough ****** About BCAL Diagnostics BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a blood test for the detection of breast cancer, with results to date demonstrating excellent performance. The test is initially designed to complement current imaging technologies, such as the mammogram, with a future aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes. Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). Copyright © BCAL Diagnostics 2024. All rights reserved. Our mailing address is: SUITE 506 LEVEL 5 50 CLARENCE STREET Sydney New South Wales 2000 Want to change how you receive these emails? You canupdate your preferencesorunsubscribe from this list.